Kyndryl stock slumped after Q3 results and a governance surprise on February 9. Shares of KD fell to US$10.59 after adjusted EPS of US$0.52 missed the US$0.60 estimate and revenue of US$3.86 billion also trailed forecasts. Management disclosed an internal accounting review alongside the CFO’s departure, raising uncertainty. For Canadian investors, the mix of a KD earnings miss, leadership change, and review findings narrows near‑term visibility and puts guidance in focus. We break down the data and next steps.

Q3 Results and Market Reaction

Kyndryl reported adjusted EPS of US$0.52 versus the US$0.60 consensus and revenue of US$3.86 billion, missing on both lines. The softer print resets expectations after a solid run into late 2025. The company did not issue detailed changes to its outlook tied to the quarter, keeping near‑term visibility tight. For context on the headline miss and estimates, see the coverage at Yahoo Finance.

Kyndryl stock plunged 54.93% to US$10.59, with volume surging to 60,654,604 shares versus a 2,239,362 average. The session ranged between US$10.10 and US$11.43. The 52‑week range now stands at US$10.11 to US$44.20, with shares down 58.47% year to date and 74.20% over one year. The magnitude reflects both the KD earnings miss and fresh governance risk.

CFO Exit and Accounting Review

Management disclosed the CFO’s departure and an internal accounting review, which amplified downside pressure. While details are limited, reviews can delay filings, alter prior results, or add controls. Until findings are clear, risk premia rise. For initial headlines on the disclosure and reaction, see Bloomberg.

Accounting reviews introduce uncertainty about reported metrics and future guidance. Investors will want clarity on scope, periods impacted, and any control weaknesses. A clean outcome could stabilize Kyndryl stock. Any restatement, delay, or leadership turnover beyond the CFO could extend pressure. In our view, risk control matters most now: position sizing, time horizon, and waiting for verified updates.

Valuation, Balance Sheet and Cash

At US$10.59, Kyndryl trades at a 6.19x P/E on TTM EPS of US$1.71 and a 0.162x price‑to‑sales ratio. EV/EBITDA is 2.48x, suggesting depressed expectations. Leverage is elevated: debt‑to‑equity stands at 3.25x, with a current ratio of 1.07x. These metrics screen as inexpensive, but balance‑sheet risk and event uncertainty can keep multiples low until clarity improves.

Operating cash flow per share is US$2.57, but free cash flow per share is negative at US$‑0.19, reflecting investment and timing. Cash per share is US$7.62. Interest coverage is 6.12x and net debt/EBITDA sits at 1.17x, both manageable. That said, Kyndryl stock will likely track updates on any review‑related costs, audit timing, and cash conversion through fiscal 2026.

What Canadian Investors Should Watch Next

Analysts show 4 Buys, 0 Holds, 0 Sells (consensus 4.00). Our system grade is B with a Neutral stance, reflecting mixed factors: strong ROE, low EV/EBITDA, but weak DCF and elevated leverage. Divergence like this often resolves with new information. Kyndryl stock needs clean review outcomes and credible guidance to rebuild trust.

Focus on management updates from the accounting review, any change to guidance, and the next earnings date on May 6, 2026. Canadian investors using U.S. listings should account for FX costs and liquidity. Until findings are public, consider tighter risk limits, staged entries, or waiting for a higher‑quality tape before adding exposure to Kyndryl stock.

Final Thoughts

Kyndryl’s quarter missed on earnings and revenue, then a CFO departure and an internal accounting review triggered a steep selloff. Valuation screens cheap on P/E, price‑to‑sales, and EV/EBITDA, but leverage is high and free cash flow is soft. For Canadian investors, patience may help. We suggest watching for clear review outcomes, stable guidance, and improving cash conversion before scaling positions. Tactically, smaller allocations, stop‑loss discipline, and a focus on liquidity can manage downside. If governance risk fades and execution stabilizes, Kyndryl stock could re‑rate, but proof points must come first. This is not investment advice; do your own research.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.